Document Detail


The antiprogestins: a recent advance in fertility regulation.
MedLine Citation:
PMID:  3320545     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
RU 468 (mifepristone) is the first antiprogestin available for clinical purposes. Its pharmacological properties are presented. It possesses antiprogestin and antiglucocorticoid activities. It is now in phase II-III clinical studies as a fertility control agent. The drug appears useful per se in four circumstances: (1) for early pregnancy (amenorrhea of less than 5 weeks' duration). Complete interruption is obtained in approximately 90% of women with a single dose of 600 mg. For this stage of pregnancy, RU 486 appears to be an interesting alternative to vacuum aspiration; (2) for late occasional luteal contraception when given as a single dose on the date of the expected period in women at risk of pregnancy; (3) for dead fetus expulsion in the 2nd or 3rd trimester of pregnancy, and (4) for cervical ripening before obstetrical procedures in pregnant women, such as D and C or vacuum aspiration. The antiglucocorticoid activity of the molecule can be demonstrated in humans by a rise in plasma cortisol, ACTH and LPH after RU 486 intake, and by blockade of some peripheral effects of cortisol. Results obtained in more than 1000 women undergoing short-term treatment with RU 486 (600 or 800 mg once) clearly indicate that the antiglucocorticoid activity of the molecule has no clinical relevance at the doses used for fertility control purposes. In conclusion, RU 486 appears to be a promising new tool for fertility control, but large-scale trials are necessary to confirm its safety and to define its optimal mode of utilization for each indication.
Authors:
A Ulmann
Related Documents :
15271485 - Low dose insemination in the mare: an update.
22889435 - Planned and unplanned pregnancy: effects on health practice and depression during pregn...
12194445 - Are temporary migrants escapees of the one-child-per-family population policy: a revisi...
17084005 - Impact of elevated co(2) and nitrogen fertilization on foliar elemental composition in ...
11155325 - In vitro fertilization and intracytoplasmic sperm injection for couples with unexplaine...
20468745 - The morning after pill.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of steroid biochemistry     Volume:  27     ISSN:  0022-4731     ISO Abbreviation:  J. Steroid Biochem.     Publication Date:  1987  
Date Detail:
Created Date:  1988-02-25     Completed Date:  1988-02-25     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0260125     Medline TA:  J Steroid Biochem     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1009-12     Citation Subset:  IM; J    
Affiliation:
Institut Roussel Uclaf, Romainville, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abortifacient Agents, Steroidal
Animals
Contraception*
Contraceptives, Oral, Synthetic
Estrenes* / adverse effects,  metabolism,  pharmacology
Female
Glucocorticoids / antagonists & inhibitors
Humans
Mifepristone
Pregnancy
Progesterone / physiology
Progestins / antagonists & inhibitors*
Receptors, Steroid / metabolism
Chemical
Reg. No./Substance:
0/Abortifacient Agents, Steroidal; 0/Contraceptives, Oral, Synthetic; 0/Estrenes; 0/Glucocorticoids; 0/Progestins; 0/Receptors, Steroid; 57-83-0/Progesterone; 84371-65-3/Mifepristone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The measurement of hormones in saliva: possibilities and pitfalls.
Next Document:  The influence of steroid hormones on the uterine cervix during pregnancy.